Effects of yeast-derived β-glucans on blood cholesterol and macrophage functionality Glucans, blood cholesterol, and macrophage function V. Vetvicka and J. Vetvickova

Journal of Immunotoxicology

Volumn 6, Issue 1, 2009, Pages 30-35

  Vetvicka, Vaclav ^b   Vetvickova, Jana ^a  

^a University of Louisville School of Medicine   (United States)

^b NONE

Author keywords

Blood; Cholesterol; Glucan; Immunocytes; Nutrition

Indexed keywords

BETA 1,3 GLUCAN; BETA GLUCAN; BETAMUNE 100; BETAMUNE 400; CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HYPERCHOLESTEROLEMIA; MACROPHAGE FUNCTION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; YEAST;

ANIMAL STRUCTURES; ANIMALS; BETA-GLUCANS; BLOOD; CHOLESTEROL; DIETARY CARBOHYDRATES; FEMALE; HYPERCHOLESTEROLEMIA; MACROPHAGE ACTIVATION; MACROPHAGES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICROSPHERES; MONOCYTES; ORGAN SIZE; PHAGOCYTOSIS; TRIGLYCERIDES; YEASTS;

MUS;

EID: 70350468872     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910802604317     Document Type: Article

References (34)

1. Babicek, K., Cechova, I., Simon, R. R., Harwood, M., and Cox, D. J. 2007. Toxicological assessment of a particulate yeast (1,3/1,6)-β-D-glucan in rats. Food. Chem. Toxicol. 45:1719-1730.
2. Benacerraf, B., and Sebestyen, M. M. 1957. Effect of bacterial endotoxins on the reticuloendothelial system. Fed. Proc. 16:860-867.
3. Bengtsson, S., Aman, P., Graham, H., Newman, C. W., and Newman, P. K. 1989. Chemical studies on mixed linked β-glucans in naked barley cultivars giving different hypocholesterolemic responses in chicken. J. Agric. Food Sci. 52:435-445.
4. Black, W. A., Cornhill, W. J., Dewar, E. T., and Woodward, F. N. 1951. Manufacture of algal chemicals. III. Laboratory scale isolation of laminarin from brown marine algae. J. Appl. Chem. 1:505-507.
5. Davidson, M. H., Dugan, L. D., Burns, J. H., Bova, J., Story, K., and Drennan, K. B. 1991. The hypocholesterolemic effects of β-glucan in oatmeal and oat bran. A dose-controlled study. JAMA 265:1833-1839.
6. Delaney, B., Nicolosi, R. J., Wilson, T. A., Carlson, T., Frazer, S., Zheng, G. H., Hess, R., Ostergren, K., Haworth, J., and Knutson, N. 2003. β-Glucan fractions from barley and oats are similarly anti-atherogenic in hypercholesterolemic Syrian golden hamsters. J. Nutr. 133:468-475.
7. Di Luzio, N. R., Williams, D. L., McNamee, R. B., Edwards, B. F., and Kitahama, A. 1979. Comparative tumor-inhibitory and antibacterial activity of soluble and particulate glucan. Int. J. Cancer 24:773-779.
8. Fadel, J. G., Newman, R. K., Newman, C. W., and Barnes, A. E. 1987. Hypocholesterolemic effects of β-glucans in different barley diets fed to broiler chicks. Nutr. Rep. Int. 35:1049-1058.
9. Frey, T., and De Maio, A. 2007. Increased expression of CD14 in macrophages after inhibition of the cholesterol biosynthetic pathway by lovastatin. Mol. Med. 13:592-604.
10. Hamuro, J. 2005. Anti-cancer immunotherapy with perorally effective lentinan. Gan. To Kagaku Ryoho 32:1209-1215.
11. Harada, T., Misaki, A., and Saito, H. 1968. Curdlan: A bacterial gel-forming β-1,3-glucan. Arch. Biochem. Biophys. 124:292-298.
12. Hong, F., Yan, J., Baran, J. T., Allendorf, D. J., Hansen, R. D., Ostroff, G. R., Xing, P. X., Cheung, N. K., and Ross, G.D. 2004. Mechanism by which orally administered β-1,3-glucans enhance the tumoricidal activity of anti-tumor monoclonal antibodies in murine tumor models. J. Immunol. 173:97-806.
13. Kahlon, T. S., Chow, F. I., Knuckles, B. E., and Chiu, M. M. 1993. Cholesterol-lowering effects in hamsters of β-glucan-enriched barley fraction, dehulled whole barley, rice bran, and oat bran and their combinations. Cereal Chem. 70:435-440.
14. Keogh, G. F., Cooper, G. J., Mulvey, T. B., McArdle, B. H., Coles, G. D., Monro, J. A., Poppitt, S. D. 2003. Randomized controlled crossover study of the effect of a highly β-glucan-enriched barley on cardiovascular disease risk factors in mildly hypercholesterolemic men. Am. J. Clin. Nutr. 78:711-718.
15. Keys, A., Anderson, J. T., and Grande, F. 1960. Diet-type (fast constant) and blood lipid in man. J. Nutr. 70:257-266.
16. Li, B., Allendorf, D. J., Hansen, R., Marroquin, J., Ding, C., Cramer, D. E., and Yan, J. 2006. Yeast β-glucan amplifies phagocyte killing of iC3bopsonized tumor cells via complement receptor 3-Syk-Phosphatidylinositol 3-kinase pathway. J. Immunol. 177:1661-1669.
17. Malkki, Y. 2001. Oat fiber; In: Handbook of Dietary Fiber(Eds. Cho, S. S., and Dreher, M. L.), New York: Marcel Dekker, pp. 497-512.
18. Mimura, H., Ohno, N., Suzuki, I., and Yadomae, T. 1985. Purification, antitumor activity, and structural characterization of β-1,3-glucan from Peziza vesiculosa. Chem. Pharm. Bull. 33:5096-5099. (Pubitemid 16181352)
19. Newman, R. K., Klopfenstein, C. F., Newman, C. W., Guritno, N., and Hofer, P. J. 1992. Comparison of the cholesterol-lowering properties of whole barley, oat bran, and wheat red dog in chicks and rats. Cereal Chem. 69:240-244.
20. Nicolosi, R., Bell, S. J., Bistrian, B. R., Greenberg, I., Forse, R. A., and Blackburn, G. L. 1999. Plasma lipid changes after supplementation with β-glucan fiber from yeast. Am. J. Clin. Nutr. 70:208-212.
21. Pandey, R. S., Birenda, K. T., and Tripathi, Y. B. 2005. Exact of gum resins of Boswellia serrata L. inhibits lipopolysaccharide induced nitric oxide production in rat macrophages along with hypolipidemic property. Indian J. Exp. Biol. 43:509-516.
22. Queenan, K. M., Stewart, M. L., Smith, K. N., Thomas, W., Fulcher, R. G., and Slavin, J. L. 2007. Concentrated oat β-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial. Nutrition J. 6:1-8.
23. Reyna-Villasmil, N., Bermudez-Pirela, V., Mengual-Moreno, E., Arias, N., Cano-Ponce, C., Leal-Gonzales, E., Suiki, A., Inglett, G. E., Israili, Z. H., Hernandez-Hernandez, R., and Velasco, M. 2007. Oat-derived β-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia. Am. J. Therapeut. 14:203-212.
24. Rigi, S. J., and Di Luzio, N. R. 1961. Identification of a reticuloendothelial stimulating agent in zymosan. Am. J. Physiol. 200:297-300.
25. Schaefer, E. J., Lamon-Fava, S., Ausman, L. M., Ordovas, J. M., Clevidence, B. A., Judd, J. T., Goldin, B. R., Woods, M., Gorbach, S., and Lichtenstein, A. H. 1997. Individual variability in lipoprotein cholesterol response to National Cholesterol Education Program Step 2 diets. Am. J. Clin. Nutr. 65:823-830.
26. Schnmitz, G., Robenek, H., and Assmann, G. 1986. Role of the high density lipoprotein-receptor cycle in macrophage-cholesterol metabolism. Klin. Wochenschrift 64:979-985.
27. Tietyen, J. L., Nevins, D. J., and Schneeman, B. O. 1990. Characterization of the hypocholesterolemic potential of oat brand. FASEB J. 4:A527.
28. Vetvicka, V., Holub, M., Kovaru, H., Siman, P., and Kovaru, F. 1988. α-Fetoprotein and phagocytosis in athymic nude mice. Immunol. Lett. 19:95-98.
29. Vetvicka, V., Vashishta, A., Saraswat-Ohri, S., and Vetvickova, J. 2008. Immunological effects of yeast- and mushroom-derived β-glucans. Biofactors (in press).
30. Vetvicka, V., and Vetvickova, J. 2007. An evaluation of the immunological activities of commercially available β-1,3-glucans. JANA 10:25-31.
31. Vetvicka, V., and Yvin, J. C. 2004. Effects of marine β-1,3 glucan on immune reactions. Int. Immunopharmacol. 4:721-730.
32. Wang, L., Behr, S. R., Newman, R. K., and Newman, C. W. 1997. Comparative cholesterol-lowering effects of barley β-glucan and barley oil in golden Syrian hamsters. Nutr. Res. 17:77-88.
33. Yan, J., Zong, H., Shen, A., Chen, S., Yin, X., Liu, W., Gu, X., and Gu, J. 2003. The β-(1-6)-branched β-(1-3) glucohexaose and its analogues containing an α-(1-3)-linked bond have similar stimulatory effects on the mouse spleen as Lentinan. Int. Immunopharmacol. 3:1861-1871.
34. Yan, J., Allendorf, D. J., and Brandley, B. 2005. Yeast whole glucan particle (WGP) β-glucan in conjunction with anti-tumor monoclonal antibodies to treat cancer. Expert Opin. Biol. Ther. 5:691-702.